Collegium Pharmaceutical, Inc.
US ˙ NasdaqGS ˙ US19459J1043

Introduction

This page provides a comprehensive analysis of the known insider trading history of David Hirsch. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David Hirsch has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RPID / Rapid Micro Biosystems, Inc. Director 14,300
Director 25,833
US:TCDA / Tricida Inc Director 57,235
US:MTEM / Molecular Templates, Inc. Director 15,000
US:COLL / Collegium Pharmaceutical, Inc. Director 8,095
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Hirsch. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases COLL / Collegium Pharmaceutical, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in COLL / Collegium Pharmaceutical, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COLL / Collegium Pharmaceutical, Inc. Insider Trades
Insider Sales COLL / Collegium Pharmaceutical, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in COLL / Collegium Pharmaceutical, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2019-11-08 COLL Hirsch David 25,000 19.3300 25,000 19.3300 483,250 131 13.8900 -136,000 -28.14
2019-08-29 COLL Hirsch David 22,106 11.6500 22,106 11.6500 257,535

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COLL / Collegium Pharmaceutical, Inc. Insider Trades
Insider Purchases RPID / Rapid Micro Biosystems, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in COLL / Collegium Pharmaceutical, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RPID / Rapid Micro Biosystems, Inc. Insider Trades
Insider Sales RPID / Rapid Micro Biosystems, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in COLL / Collegium Pharmaceutical, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RPID / Rapid Micro Biosystems, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David Hirsch as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-05-28 2024-05-23 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock
A - Award 14,300 14,300
2021-07-26 2021-07-23 4 PSTX Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 25,833 25,833
2021-07-20 2021-07-19 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Common Stock Warrant
C - Conversion 129,032 129,032
2021-07-20 2021-07-19 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Series B1 Warrant
C - Conversion -645,160 0 -100.00
2021-07-20 2021-07-19 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Common Stock Warrant
C - Conversion 500,000 500,000
2021-07-20 2021-07-19 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Series A1 Warrant
C - Conversion -2,500,000 0 -100.00
2021-07-20 2021-07-19 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Series C1 Preferred Stock
C - Conversion -2,291,665 0 -100.00
2021-07-20 2021-07-19 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Series B1 Preferred Stock
C - Conversion -5,654,529 0 -100.00
2021-07-20 2021-07-19 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Series A1 Preferred Stock
C - Conversion -8,774,007 0 -100.00
2021-07-20 2021-07-19 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock
C - Conversion 3,344,038 3,407,952 5,232.09
2021-07-15 2021-07-14 4 RPID RAPID MICRO BIOSYSTEMS, INC.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2021-07-14 3 RPID RAPID MICRO BIOSYSTEMS, INC.
Class A Common Stock
63,914
2021-06-17 2021-06-16 4 PSTX Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 20,000 20,000
2021-06-11 2021-06-10 4 TCDA Tricida, Inc.
Stock Option (right to buy)
A - Award 57,235 57,235
2021-06-11 2021-06-10 4 TCDA Tricida, Inc.
Common Stock
A - Award 16,403 27,584 146.70
2021-06-04 2021-06-03 4 MTEM Molecular Templates, Inc.
Stock Option (right to buy)
A - Award 15,000 15,000
2020-07-15 2020-07-14 4 PSTX Poseida Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -491,159 0 -100.00
2020-07-15 2020-07-14 4 PSTX Poseida Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -2,581,755 0 -100.00
2020-07-15 2020-07-14 4 PSTX Poseida Therapeutics, Inc.
Common Stock
P - Purchase 250,000 2,714,245 10.15 16.00 4,000,000 43,427,920
2020-07-15 2020-07-14 4 PSTX Poseida Therapeutics, Inc.
Common Stock
C - Conversion 2,464,245 2,464,245
2020-07-13 2020-07-09 4 PSTX Poseida Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 20,000 20,000
2020-06-15 2020-06-11 4 TCDA Tricida, Inc.
Stock Option (right to buy)
A - Award 22,967 22,967
2020-06-15 2020-06-11 4 TCDA Tricida, Inc.
Common Stock
A - Award 5,670 11,181 102.89
2020-06-01 2020-05-28 4 MTEM Molecular Templates, Inc.
Stock Option (right to buy)
A - Award 15,000 15,000
2020-05-28 2020-05-26 4 MTEM Molecular Templates, Inc.
Common Stock
J - Other 1,649 1,649
2020-05-28 2020-05-26 4 MTEM Molecular Templates, Inc.
Common Stock
J - Other -1,000,000 3,199,035 -23.81
2020-05-22 2020-05-20 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Stock Option (Right to Purchase)
A - Award 8,095 8,095
2020-05-22 2020-05-20 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
A - Award 4,047 21,164 23.64
2019-12-05 2019-11-25 4/A MTEM Molecular Templates, Inc.
Common Stock
P - Purchase 937,500 4,199,035 28.74 8.00 7,500,000 33,592,280
2019-11-27 2019-11-25 4 MTEM Molecular Templates, Inc.
Common Stock
P - Purchase 937,000 4,198,535 28.73 8.00 7,496,000 33,588,280
2019-11-13 2019-11-08 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
S - Sale -25,000 17,117 -59.36 19.33 -483,250 330,872
2019-09-03 2019-08-29 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Stock Option (Right to Purchase)
M - Exercise -19,853 0 -100.00
2019-09-03 2019-08-29 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
S - Sale -22,106 42,117 -34.42 11.65 -257,535 490,663
2019-09-03 2019-08-29 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
M - Exercise 19,853 64,223 44.74 9.33 185,228 599,201
2019-06-04 2019-05-31 4 TCDA Tricida, Inc.
Stock Option (right to buy)
A - Award 7,068 7,068
2019-06-04 2019-05-31 4 TCDA Tricida, Inc.
Common Stock
A - Award 1,879 5,511 51.73
2019-05-30 2019-05-29 4 MTEM Molecular Templates, Inc.
Stock Option (right to buy)
A - Award 15,000 15,000
2019-04-29 2019-04-25 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Stock Option (Right to Purchase)
A - Award 9,414 9,414
2019-04-29 2019-04-25 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
A - Award 4,707 44,370 11.87
2018-09-25 2018-09-21 4 MTEM Molecular Templates, Inc.
Common Stock
P - Purchase 365,000 3,261,535 12.60 5.50 2,007,500 17,938,442
2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Stock Option (right to buy)
A - Award 13,147 13,147
2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Series D Convertible Preferred Stock
C - Conversion -1,817,447 0 -100.00
2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Series C Convertible Preferred Stock
C - Conversion -9,677,419 0 -100.00
2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock
A - Award 3,632 3,632
2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock
P - Purchase 131,579 3,019,734 4.56 19.00 2,500,001 57,374,946
2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock
C - Conversion 456,644 2,888,155 18.78
2018-07-02 2018-07-02 4 TCDA Tricida, Inc.
Common Stock
C - Conversion 2,431,511 2,431,511
2018-06-04 2018-05-31 4 MTEM Molecular Templates, Inc.
Stock Option (right to buy)
A - Award 15,000 15,000
2018-05-29 2018-05-24 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Stock Option (Right to Purchase)
A - Award 4,506 4,506
2018-05-29 2018-05-24 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
A - Award 2,253 27,193 9.03
2017-12-12 2017-12-08 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
S - Sale -19,650 45,620 -30.11 17.34 -340,731 791,051
2017-12-12 2017-12-08 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
S - Sale -980,350 2,276,222 -30.10 17.34 -16,999,269 39,469,689
2017-10-11 2017-10-09 4 MTEM Molecular Templates, Inc.
Stock Option (right to buy)
A - Award 25,000 25,000
2017-08-10 3 MTEM Molecular Templates, Inc.
Common Stock
5,793,070
2017-08-10 3 MTEM Molecular Templates, Inc.
Common Stock
5,793,070
2017-05-25 2017-05-24 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Stock Option (Right to Purchase)
A - Award 19,853 19,853
2016-06-13 2016-06-09 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Stock Option (Right to Purchase)
A - Award 8,700 8,700
2015-09-14 2015-09-10 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Stock Option (Right to Purchase)
A - Award 15,000 15,000
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Series D Convertible Stock
C - Conversion -101,128 0 -100.00
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Series D Convertible Stock
C - Conversion -5,045,381 0 -100.00
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Series C Convertible Stock
C - Conversion -63,356 0 -100.00
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Series C Convertible Stock
C - Conversion -3,160,905 0 -100.00
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Series B Convertible Stock
C - Conversion -257,303 0 -100.00
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Series B Convertible Stock
C - Conversion -12,837,935 0 -100.00
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
P - Purchase 3,930 65,270 6.41 12.00 47,160 783,240
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
C - Conversion 14,868 61,340 31.99
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
C - Conversion 9,182 46,472 24.62
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
C - Conversion 37,290 37,290
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
P - Purchase 196,070 3,256,572 6.41 12.00 2,352,840 39,078,864
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
C - Conversion 741,830 3,060,502 31.99
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
C - Conversion 458,102 2,318,672 24.62
2015-05-13 2015-05-12 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
C - Conversion 1,860,570 1,860,750 1,033,650.00
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)